These include interleukins, nuclear kappa factor-beta 2 (NFKB2), VEGFR/KDR, as well as the hepatocyte growth factor (HGF) and its receptor MET. Six HGF/MET mutations in the sites of interaction and binding domain, respectively, were identified in secondary lymphedema, suggesting that altering this pathway can increase individual risk of developing lymphedema after breast surgery and thus providing a new potential therapeutic target (66). This evidence concerns the gene MET and lymphedema.